Cargando…
Spesolimab: First Approval
Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flare...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744699/ https://www.ncbi.nlm.nih.gov/pubmed/36418672 http://dx.doi.org/10.1007/s40265-022-01801-4 |